Reviews and ratings for acetaminophen/hydrocodone when used in the treatment of rheumatoid arthritis. 26 reviews submitted.
Vicodin has been better because of fewer side effects.". Vicodin (acetaminophen / hydrocodone): "I have tried different medications (Diladuids, Percocet ) as I have had 2 knee replacements and another because 1 became infected.
Deafdog50 January 23, 2016.
Catpan July 29, 2013.
Anonymous February 17, 2011.
49 users found this comment helpful. Did you? Yes No| Report inappropriate "Very well tolerated".
Anonymous February 14, 2011.
car53 (taken for 1 to 2 years) October 15, 2013.
Anonymous August 8, 2012.
Did you? Yes No| Report inappropriate.
Your Stories. Each individual affected by spondylitis has their own unique story. We at SAA believe that each and every story can be a source of inspiration and empowerment. We'd love your story as well! Send it to us at elin@.
Thursday, October 06, 2016.
In 2008, I began trying different kinds of medications: NSAIDs, DMARDs, and then biologics. I hate confrontation so much that I always follow the letter of the law, and yet I decided to start taking a narcotic of all the evil things!. By the end of 2009, after failing two of the three biologics available at the time, I started taking hydrocodone for pain relief. I am the type of person who has never had detention; I don’t drink alcohol – not even socially; I have never done drugs and to my friends’ dismay never caved in to peer pressure, even in college.
Hydrocodone/acetaminophen is a narcotic pain medication used to treat arthritis and other chronic pain conditions.
Mothers who are breastfeeding should not use hydrocodone/acetaminophen since it is excreted in breast milk.
09/01/2010. http://www.nlm.nih.gov/medlineplus/druginfo/meds/a601006.html Article Article Article Article Article Article Article Article Article Article Article Article List Article Article Article Article Article Article Article. MedlinePlus. Hydrocodone.
Thank you,, for signing up.
There are also adverse events related to the central nervous system, gastrointestinal system, genitourinary system, respiratory system, the senses, and dermatology:
This site complies with the HONcode standard for trustworthy health information: verify here.
People who previously exhibited hypersensitivity to hydrocodone or acetaminophen should not take medications with these active ingredients.
Special Instructions for Pregnant Women.
Signs and symptoms of overdose include respiratory depression, extreme sleepiness that progresses to coma, skeletal muscle flaccidity (limpness), cold or clammy skin, bradycardia (slow heartbeat), and hypotension ( low blood pressure ).
In 2014 hydrocodone-containing medications will likely be upgraded to Schedule II, making them a challenge to prescribe. pain in all age groups is not available,” wrote David Borenstein MD, a rheumatologist with Arthritis and Rheumatism Associates of Washington DC, a member of the Task Force, and.
Unquestionably, the FDA’s plan to reclassify hydrocodone-acetaminophen combinations from Schedule III to Schedule II status,1 intended to address the increased abuse and overdose deaths related to these drugs, will make life more difficult for those rheumatology patients who rely on Vicodin or similar drugs for chronic pain. These are the preferred opioids among risk-averse users such as women, the elderly, and non-injecting users -- just the types of patients most likely to see a rheumatologist.2.
Another option he suggests is tramadol, a non-opioid that works on opioid receptors.
The DEA moves pain pills that contain hydrocodone from Schedule III to Schedule II.
“Schedule II is the strongest level of control on a legal prescription drug.”. “This will actually affect patient access to the medication,” explains Donald Miller, PharmD, chair of the Pharmacy Practice Department at North Dakota State University in Fargo.
The DEA notes that hydrocodone, which is taken orally for moderate to severe pain, “is associated with more drug abuse and diversion than any other licit or illicit opioid.”
Food and Drug Administration (FDA) advisory committee voted 19 to 10 in favor of the change in 2013.